Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.44 |
| ▸ | BMPR1B | O00238 | 4/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 4/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.43 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | APAF1 | O14727 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890085 | 0.90 | BRD4 (0.47) | BRD4GAAALDH1A1ATAD2BMPR1B | |
| SCHEMBL9667549 | 0.84 | BRD4 (0.49) | BRD4GAAALDH1A1ATAD2BMPR1B | |
| SCHEMBL4884442 | 0.82 | POLB (0.51) | GAAALDH1A1BMPR1BBMPR1AACVRL1 | |
| SCHEMBL9667236 | 0.80 | BRD4 (0.48) | BRD4GAAALDH1A1ATAD2BMPR1B | |
| SCHEMBL11526516 | 0.78 | BRD4 (0.55) | BRD4GAAALDH1A1ATAD2BMPR1B | |
| SCHEMBL10746214 | 0.77 | BRD4 (0.48) | BRD4GAAALDH1A1ATAD2BMPR1B | |
| SCHEMBL399175 | 0.76 | BRD4 (0.56) | BRD4GAAALDH1A1ATAD2BMPR1B | |
| SCHEMBL9665333 | 0.75 | BRD4 (0.55) | BRD4GAAALDH1A1ATAD2BMPR1B | |
| SCHEMBL4105161 | 0.75 | ATAD2 (0.74) | BRD4GAAALDH1A1ATAD2BMPR1B | |
| SCHEMBL30661535 | 0.75 | ATAD2 (0.74) | BRD4GAAALDH1A1ATAD2BMPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | PFIZER INC | 2008-10-30 | — | — | US | disclosed |
| EP-1757292-A1 | Method of treating ocd and tic disorders | Pfizer Products Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1633361-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1626722-A1 | METHOD FOR ENHANCING COGNITION USING ZIPRASIDONE | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| EP-1626723-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | disclosed |
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | PFIZER INC | 2005-02-17 | — | — | US | disclosed |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | PFIZER INC | 2005-01-20 | — | — | US | disclosed |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | PFIZER INC | 2005-01-06 | — | — | US | disclosed |
| WO-2004100955-A1 | ANXIETY TREATMENTS WITH ZIPRASIDONE | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004100957-A1 | TREATMENT OF BIPOLAR DISORDERS AND ASSOCIATED SYMPTOMS | PFIZER PRODUCTS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | HOWARD HARRY R (US) | 2002-01-10 | — | — | US | disclosed |
| US-6245766-B1 | USING A PIPERAZINE COMPOUND | PFIZER INC | 2001-06-12 | — | — | US | disclosed |
| US-6127373-A | Method of treating tourette's syndrome and obsessive compulsive disorder | PFIZER INC. (US) | 2000-10-03 | — | — | US | disclosed |
| EP-0985414-A2 | Method of treating glaucoma and ischemic retinopathy | Pfizer Products Inc. (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0931547-A1 | Piperazinyl-heterocyclic compounds in the treatment of psychiatric conditions | Pfizer Products Inc. (US) | 1999-07-28 | — | — | EP | disclosed |
| EP-0901789-A1 | Method of treating tourette's syndrome | Pfizer Products Inc. (US) | 1999-03-17 | — | — | EP | disclosed |
| EP-0281309-B1 | PIPERAZINYL-HETEROCYCLIC COMPOUNDS | PFIZER INC. (US) | 1991-12-27 | — | — | EP | disclosed |
| US-4883795-A | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1989-11-28 | — | — | US | disclosed |
| US-4831031-A | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity | PFIZER INC. (US) | 1989-05-16 | — | — | US | disclosed |
| EP-0281309-A1 | Piperazinyl-heterocyclic compounds | PFIZER INC. (US) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038036-A1 | Stabilization patient; antidepressant; psychological disorders; mood cycles | MC2R, NR3C1, CRH | BRD4 1962/4885GAA 1851/4885ALDH1A1 1321/4885 |
| US-20020004504-A1 | METHOD OF TREATING GLAUCOMA AND ISCHEMIC RETINOPATHY | ALDH1A2, NDUFB7, PTGS1 | BRD4 4582/4885GAA 330/4885ALDH1A1 204/4885 |
| US-20050014764-A1 | Method for enhancing cognition using ziprasidone | DBH, RAP1A, GABRR1 | BRD4 861/4885GAA 164/4885ALDH1A1 1775/4885 |
| US-20080269246-A1 | METHOD FOR TREATING PEDIATRIC BIPOLAR DISORDER | GABBR1, GABRR1, GABBR2 | BRD4 610/4885GAA 148/4885ALDH1A1 1399/4885 |
| US-20050004138-A1 | Anxiety treatments with ziprasidone | NPSR1, AVPR1B, SLC39A3 | BRD4 3003/4885GAA 568/4885ALDH1A1 992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.